Five-year update of a phase III trial in 994 adults with high-risk clear cell kidney cancer after surgery: adjuvant pembrolizumab vs placebo improved disease-free survival (60.9% vs 52.2%; HR 0.71) and overall survival (87.7% vs 82.3%; HR 0.66).
RCTn = 994
Haas et al. Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: five-year results from the phase III KEYNOTE-564 study